$51.9 M

KRBP Mkt cap, 09-Sept-2021
Kiromic Biopharma Net income (FY, 2020)-19.2 M
Kiromic Biopharma EBIT (FY, 2020)-19.2 M
Kiromic Biopharma Cash, 31-Dec-202010.2 M
Kiromic Biopharma EV42.2 M
Get notified regarding key financial metrics and revenue changes at Kiromic BiopharmaLearn more
Banner background

Kiromic Biopharma Income Statement

Annual

USDFY, 2018FY, 2019FY, 2020

R&D expense

1.4m1.2m5.1m

General and administrative expense

1.8m2.5m14.1m

Operating expense total

3.2m3.7m19.2m

EBIT

(3.2m)(3.7m)(19.2m)

Interest expense

633.1k22.5k

Pre tax profit

(3.8m)(3.7m)

Income tax expense

Net Income

(3.8m)(3.7m)(19.2m)

EPS

(1.3)(1.4)

Quarterly

USDQ2, 2019Q3, 2019Q2, 2020Q3, 2020

R&D expense

125.9k1.2m1.3m272.1k

General and administrative expense

143.1k1.2m10.1m607.4k

Operating expense total

269.0k2.4m11.4m879.5k

EBIT

(269.0k)(2.4m)(11.4m)(879.5k)

Interest expense

11.4k7.4k

Pre tax profit

(280.4k)(2.4m)(11.4m)(886.9k)

Net Income

(280.4k)(2.4m)(11.4m)(886.9k)

EPS

(0.1)(0.6)(3.8)(0.3)

Kiromic Biopharma Balance Sheet

Annual

USDFY, 2018FY, 2019FY, 2020

Cash

384.3k1.9m10.2m

Prepaid Expenses

588.8k

Inventories

16.3k22.2k

Current Assets

560.2k2.0m10.7m

PP&E

298.0k587.9k2.1m

Total Assets

876.0k2.7m12.8m

Accounts Payable

219.1k452.4k665.2k

Short-term debt

468.2k

Current Liabilities

610.7k673.7k1.5m

Total Debt

468.2k

Total Liabilities

610.7k673.7k1.5m

Common Stock

1.2k

Preferred Stock

8.7m10.4m

Additional Paid-in Capital

10.2m14.0m53.0m

Retained Earnings

(18.7m)(22.4m)(41.6m)

Total Equity

265.3k2.0m11.4m

Financial Leverage

3.3 x1.3 x1.1 x

Quarterly

USDQ3, 2020Q3, 2020

Cash

1.7m469.3k

Inventories

22.2k22.2k

Current Assets

2.5m1.5m

PP&E

1.3m1.6m

Total Assets

3.9m3.2m

Accounts Payable

1.3m1.7m

Short-term debt

115.6k105.6k

Current Liabilities

1.8m2.3m

Total Debt

115.6k105.6k

Total Liabilities

1.8m2.3m

Preferred Stock

11.5m11.5m

Additional Paid-in Capital

26.3m27.5m

Retained Earnings

(35.6m)(38.1m)

Total Equity

2.1m928.6k

Debt to Equity Ratio

0.1 x0.1 x

Debt to Assets Ratio

0 x0 x

Financial Leverage

1.9 x3.4 x

Kiromic Biopharma Cash Flow

Annual

USDFY, 2018FY, 2019FY, 2020

Net Income

(3.8m)(3.7m)(19.2m)

Depreciation and Amortization

80.9k87.5k200.0k

Accounts Receivable

(18.9k)24.3k

Inventories

(5.9k)

Accounts Payable

(4.4k)293.4k(7.7k)

Cash From Operating Activities

(2.2m)(2.9m)(6.1m)

Purchases of PP&E

(137.3k)(302.7k)(1.5m)

Cash From Investing Activities

(137.3k)(302.7k)(1.5m)

Short-term Borrowings

(188.1k)

Cash From Financing Activities

1.6m4.8m15.8m

Net Change in Cash

(665.2k)1.5m8.2m

Interest Paid

3.1k

Quarterly

USDQ2, 2019Q3, 2019Q2, 2020Q3, 2020

Net Income

(671.3k)(1.6m)(13.2m)(15.6m)

Depreciation and Amortization

43.0k63.7k68.5k118.9k

Accounts Receivable

(25.3k)5.0k

Inventories

(5.9k)(5.9k)

Accounts Payable

(98.2k)226.1k291.0k398.3k

Cash From Operating Activities

(400.4k)(1.0m)(2.6m)(3.6m)

Purchases of PP&E

(20.0k)(26.5k)(762.3k)(1.0m)

Cash From Investing Activities

(20.0k)(26.5k)(762.3k)(1.0m)

Short-term Borrowings

(10.0k)

Cash From Financing Activities

250.0k1.8m3.1m3.1m

Net Change in Cash

(170.4k)803.5k(245.6k)(1.5m)

Kiromic Biopharma Ratios

USDFY, 2018

Financial Leverage

3.3 x

Kiromic Biopharma Operating Metrics

Q2, 2020

Research Stage Products

2

Preclinical Phase Products

2